Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Gurunadh R. Chichili, Ling Huang, Hua Li, et al.
Science Translational Medicine (2015) Vol. 7, Iss. 289
Closed Access | Times Cited: 158

Showing 26-50 of 158 citing articles:

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
Simon Loff, Josephine Dietrich, Jan-Erik Meyer, et al.
Molecular Therapy — Oncolytics (2020) Vol. 17, pp. 408-420
Open Access | Times Cited: 85
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response
Aude De Gassart, Kieu-Suong Le, Patrick Brune, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 616
Closed Access | Times Cited: 80
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)
Georg Maschmeyer, Lars Bullinger, Carolina García‐Vidal, et al.
Leukemia (2022) Vol. 36, Iss. 5, pp. 1215-1226
Open Access | Times Cited: 45
CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
Elvira Pelosi, Germana Castelli, Ugo Testa
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2718-2718
Open Access | Times Cited: 24
Design and engineering of bispecific antibodies: insights and practical considerations
Andreas V. Madsen, Lasse Ebdrup Pedersen, Peter Kristensen, et al.
Frontiers in Bioengineering and Biotechnology (2024) Vol. 12
Open Access | Times Cited: 15
Inhibitory CARs fail to protect from immediate T cell cytotoxicity
Maximilian A. Funk, Gerwin Heller, Petra Waidhofer‐Söllner, et al.
Molecular Therapy (2024) Vol. 32, Iss. 4, pp. 982-999
Open Access | Times Cited: 13
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
Adam Root, Wei Cao, Bilian Li, et al.
Antibodies (2016) Vol. 5, Iss. 1, pp. 6-6
Open Access | Times Cited: 86
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia
Challice L. Bonifant, Árpád Szöőr, David Torres, et al.
Molecular Therapy (2016) Vol. 24, Iss. 9, pp. 1615-1626
Open Access | Times Cited: 76
Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia
Daniel Guy, Geoffrey L. Uy
Current Hematologic Malignancy Reports (2018) Vol. 13, Iss. 6, pp. 417-425
Open Access | Times Cited: 75
Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies
Brian H. Santich, Jeong A Park, Hoa Tran, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 534
Open Access | Times Cited: 68
MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
Liqin Liu, Chia‐Ying K. Lam, Vatana Long, et al.
Clinical Cancer Research (2016) Vol. 23, Iss. 6, pp. 1506-1518
Open Access | Times Cited: 67
Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer
Paul A. Moore, Kalpana Shah, Yongqiang Yang, et al.
Molecular Cancer Therapeutics (2018) Vol. 17, Iss. 8, pp. 1761-1772
Open Access | Times Cited: 65
Checkpoint Antibodies but not T Cell–Recruiting Diabodies Effectively Synergize with TIL-Inducing γ-Irradiation
Michael Hettich, Jayashree Lahoti, Shruthi Prasad, et al.
Cancer Research (2016) Vol. 76, Iss. 16, pp. 4673-4683
Open Access | Times Cited: 64
Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow
Raoufeh Ahamadi-Fesharaki, Abolfazl Fateh, Farzam Vaziri, et al.
Molecular Therapy — Oncolytics (2019) Vol. 14, pp. 38-56
Open Access | Times Cited: 64
Novel Approaches to Acute Myeloid Leukemia Immunotherapy
Ofrat Beyar‐Katz, Saar Gill
Clinical Cancer Research (2018) Vol. 24, Iss. 22, pp. 5502-5515
Closed Access | Times Cited: 60
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
Tianyu Cai, Agnès Gouble, Kathryn L. Black, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 32
Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy
Romina Marone, Emmanuelle Landmann, Anna Devaux, et al.
The Journal of Experimental Medicine (2023) Vol. 220, Iss. 12
Open Access | Times Cited: 21
Dual-targeting CD33/CD123 NANOBODY® T cell engager with potent anti-AML activity and good safety profile
Zhihong Zeng, Annelies Roobrouck, Geert Deschamps, et al.
Blood Advances (2024) Vol. 8, Iss. 9, pp. 2059-2073
Open Access | Times Cited: 8
IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells
Yi Zhang, Miso Park, Lucy Ghoda, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 7
Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity
Olivia Campagne, Audrey Delmas, Sylvain Fouliard, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 11, pp. 2631-2641
Open Access | Times Cited: 55
CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications
Anke Steinmetz, François Vallée, Christian Beil, et al.
mAbs (2016) Vol. 8, Iss. 5, pp. 867-878
Open Access | Times Cited: 50
Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection
Guido Ferrari, Barton F. Haynes, Scott Koenig, et al.
Nature Reviews Drug Discovery (2016) Vol. 15, Iss. 12, pp. 823-834
Open Access | Times Cited: 50
Bispecific antibodies in cancer immunotherapy
Siqi Chen, Jing Li, Qing Li, et al.
Human Vaccines & Immunotherapeutics (2016) Vol. 12, Iss. 10, pp. 2491-2500
Open Access | Times Cited: 49
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
Rowa Y. Alhabbab
Frontiers in Genetics (2020) Vol. 11
Open Access | Times Cited: 41
BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
Cecily Allen, Amer M. Zeidan, Jan Philipp Bewersdorf
Life (2021) Vol. 11, Iss. 6, pp. 465-465
Open Access | Times Cited: 41

Scroll to top